Phuturdex › Diseases › Astrocytoma
Drugs in development · updated 30 October 2026
Astrocytoma: drugs in development
As of 30 October 2026 there are 62 active clinical trials (recruiting or ongoing, phases I–III) on 64 drugs for astrocytoma. 20 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Safusidenib | III | 3 | NCT05303519 |
| M032 | I–II | 2 | NCT05084430 |
| DB107-FC | II | 1 | NCT06264388 |
| DB107-RRV | II | 1 | NCT06264388 |
| NEO212 Oral Capsule | I–II | 1 | NCT06047379 |
| PalacaparibAZD9574 | I–II | 1 | NCT05417594 |
| SRN-101 | I–II | 1 | NCT07902037 |
| TuvusertibM1774 | II | 1 | NCT07417761 |
| VeliparibABT-888 | II | 1 | NCT03581292 |
| ZedoresertibDebio 0123 | I–II | 1 | NCT05765812 |
| AbexinostatPCI 24781 | I | 1 | NCT05698524 |
| C134 | I | 1 | NCT06614855 |
| FT536 | I | 1 | NCT07560865 |
| G207 | I | 1 | NCT03911388 |
| IDH305 | I | 1 | NCT02381886 |
| OKN-007 | I | 1 | NCT05561374 |
| ONC206 | I | 1 | NCT04541082 |
| Telaglenastat Hydrochloride | I | 1 | NCT03528642 |
| Triapine | I | 1 | NCT06860594 |
| Fimepinostat | Early I | 1 | NCT03893487 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TemozolomideTemodal, Temodar | III | 19 | NCT00978458 |
| VorasidenibVoranigo® | III | 4 | NCT06809322 |
| VincristineVincristin, Oncovin [vincristine] | III | 2 | NCT00887146 |
| LomustineCCNU, Gleostine® | III | 1 | NCT00887146 |
| ProcarbazineMatulane® | III | 1 | NCT00887146 |
| Bevacizumabavastin, MVASI | I–II | 4 | NCT06047379 |
| NivolumabOpdivo, ONO-4538 | I–II | 4 | NCT06047379 |
| PembrolizumabKEYTRUDA, MK-3475 | I–II | 4 | NCT06047379 |
| IrinotecanOnivyde, CPT-11 | I–II | 3 | NCT01837862 |
| CarboplatinCarboplatine, Paraplatin | I–II | 2 | NCT06047379 |
| EflornithineDFMO, Difluoromethylornithine | I–II | 2 | NCT07468136 |
| IpilimumabYERVOY, ipililumab IV | I–II | 2 | NCT06047379 |
| MirdametinibGomekli®, Ezmekly® | I–II | 2 | NCT04923126 |
| RetifanlimabINCMGA00012, Zynyz® | I–II | 2 | NCT07468136 |
| AbemaciclibLY2835219, Verzenio® | II | 1 | NCT03220646 |
Sorted by most advanced phase and number of active trials. Showing 15 of 44 drugs.
All 64 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Glioblastoma 245 drugs
- Glioma 184 drugs
- Brain Neoplasms 190 drugs
- Gliosarcoma 34 drugs
- Neoplasm 671 drugs
- Ependymoma 56 drugs
- Lung neoplasm 348 drugs
- Ovarian neoplasm 411 drugs
- Pancreatic neoplasm 395 drugs
- Metastasis 493 drugs
- Melanoma 352 drugs
- Medulloblastoma 77 drugs
Broader categories
- Glandular and epithelial neoplasm 12 drugs
- Germ cell and embryonal neoplasms 35 drugs
- Nerve tissue neoplasm 4 drugs
- Neoplasm 671 drugs
- Neuroectodermal tumor 3 drugs
- Neuroepithelial neoplasm 4 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001254 “Astrocytoma”. Prevalence: Orphanet.